pharma · Colorectal Cancer Screening · Screening for Colon Cancer · MRKR
ME Therapeutics
Marker Therapeutics
ME Therapeutics is a pharma organization headquartered in Vancouver, CA. It trades on NYSE under ticker MRKR. Primary therapeutic focus areas include Colorectal Cancer Screening, Screening for Colon Cancer, Platinum Sens
Vancouver, British Columbia, CA HQ
2018 Founded
4 Employees
Public company Type
MRKR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Vancouver, British Columbia, CA
- Founded
- 2018
- Employees
- 4
- Programs
- 13
- Drugs
- 10
- Patents
- 27
FRα peptide plus Adjuvant (GM-CSF)
Phase 2 · mab · Platinum Sensitive Ovarian Cancer
FRα peptide plus Adjuvant (GM-CSF) for Platinum Sensitive Ovarian Cancer is a Phase 2 program (mab) at Marker Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code FRV-004
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Marker Therapeutics
- Phase
- Phase 2
- Modality
- mab
- Indication
- Platinum Sensitive Ovarian Cancer
- Status
- terminated
- Trials
- 1